AstraZeneca receives Investment Bank Analyst Rating Update
- ByInvesting.com-
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AstraZeneca PLC ADR (AZN)
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NASDAQ | USD | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| OTC Markets | USD | Delayed | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
54.69
+1.45(+2.72%)
After Hours
54.69
0.00(0.00%)
- Real-time Data
- Volume:7,831,454
- Day's Range:53.24 - 54.94
- 52 wk Range:52.65 - 71.70
AZN Overview
- Prev. Close
- 53.24
- Day's Range
- 53.24-54.94
- Revenue
- 41.49B
- Open
- 53.26
- 52 wk Range
- 52.65-71.7
- EPS
- -0.816
- Volume
- 7,831,454
- Market Cap
- 167.55B
- Dividend (Yield)
- 1.42(2.67%)
- Average Volume (3m)
- 6,461,822
- P/E Ratio
- -159.09
- Beta
- 0.119
- 1-Year Change
- -9.33%
- Shares Outstanding
- 1,549,495,319
- Next Earnings Date
- Nov 10, 2022
What is your sentiment on AstraZeneca ADR?
or
Market is currently closed. Voting is open during market hours.
AstraZeneca PLC ADR News
- AstraZeneca PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
- AstraZeneca (NASDAQ: AZN) Up on Positive Clinical Data and Evusheld Approval
- ByTipRanks-
Shares of AstraZeneca (NASDAQ: AZN) were on an upswing in pre-market trading on Friday as its investigational drug danicopan (ALXN2040) showed positive results in an ALPHA Phase...
AstraZeneca PLC ADR Analysis
- Oil’s Iran Cliffhanger: What To Know And What To Expect
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
- 3 Healthcare Giants Bucking The Bear Market
Healthcare stocks have been some of this year’s best performers Defensive, blue-chips with reasonable valuations and strong dividends tend to do well in a bear...
- 3 Recession-Proof Stocks To Protect Your Portfolio From Fed-Induced Turmoil
Fed's expected aggressive tightening to contain soaring inflation, has many worrying about a possible recession. Three companies to protect your portfolio due to strong...
AstraZeneca PLC ADR Company Profile
AstraZeneca PLC ADR Company Profile
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Buy | Neutral | Sell | Neutral |
| Technical Indicators | Neutral | Strong Buy | Strong Buy | Strong Sell | Sell |
| Summary | Neutral | Strong Buy | Buy | Strong Sell | Neutral |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 67.00 | 67.45 | 66.22 | +0.24 | +0.36% | 8.54M | Toronto | |||
| 85.45 | 85.94 | 83.20 | +1.05 | +1.24% | 3.26M | Toronto | |||
| 123.22 | 123.71 | 119.57 | +2.55 | +2.11% | 2.10M | Toronto | |||
| 57.41 | 57.77 | 56.81 | +0.13 | +0.23% | 739.75K | Toronto | |||
| 22.84 | 22.95 | 22.41 | +0.26 | +1.15% | 342.13K | Toronto | |||
| 27.40 | 27.43 | 26.77 | +0.41 | +1.52% | 184.82K | Toronto | |||
| 30.14 | 30.17 | 29.65 | +0.12 | +0.40% | 2.56M | Toronto | |||
| 54.74 | 54.92 | 54.25 | +0.02 | +0.04% | 1.24M | Toronto | |||
| 61.04 | 61.26 | 59.54 | +1.15 | +1.92% | 3.35M | Toronto | |||
| 22.12 | 22.19 | 21.65 | +0.34 | +1.56% | 639.16K | Toronto | |||
| 17.96 | 18.05 | 17.41 | +0.27 | +1.53% | 1.57M | Toronto | |||
| 57.97 | 58.12 | 56.76 | +1.21 | +2.13% | 5.64M | Toronto | |||
| 15.82 | 15.97 | 15.56 | +0.03 | +0.19% | 1.80M | Toronto | |||
| 33.26 | 33.61 | 33.12 | -0.04 | -0.12% | 509.02K | Toronto | |||
| 6.55 | 6.57 | 6.31 | -0.0600 | -0.91% | 12.42K | TSXV |
- Feb 11, 2021, 22:25do not buy this stock, it's a trap
- Feb 09, 2021, 07:16Junk like pfizer
- Aug 23, 2020, 18:18why is this stock so stagnant? even with good news it seems to drop.
- Aug 07, 2020, 19:35Japan, AstraZeneca agree on 120 mil. COVID-19 vaccine dose supply KYODO NEWS - 2 hours ago - 21:49 | All, Japan, Coronavirus
- Aug 14, 2020, 20:21I dont get how this company pumps out good news and a potential merger and the stock moves by pennies. what will it take for this stock to jump?
- Jul 30, 2020, 23:35Get into it before FDA approves vaccine
- May 21, 2020, 18:27is it too late to get in?
- Jul 18, 2020, 22:27Not really man,Its just the beginning.Its gonna be late 3 weeks after.
- Jul 23, 2020, 19:39I think it's a good time. this stock is stable historically and pays dividends. I bought at 62 so I'm down big but have faith it will be good long term.
- Dec 16, 2020, 19:45Danny Dambrosiorip